MedTrace Logo

Daptomycin With Rifampin for Treatment of Staphylococcal Prosthetic Joint Infection

NCT01144000 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2012-06-26

No results posted yet for this study

Summary

To determine the outcome and safety of a combined antimicrobial treatment involving daptomycin and surgical approach involving retention or short-interval two-stage exchange of the implant. Patients with hip, knee and shoulder Prosthetic Joint Infection (PJI) caused by methicillin-susceptible and methicillin-resistant staphylococci will be included and followed during 2 years.

Conditions

  • Staphylococcal Infections

Interventions

DRUG

Daptomycin

10mg/kg/24h i.v.(intravenous) for 2-3 weeks with/or without rifampin (depending if the prosthesis is removed or not)

Sponsors & Collaborators

  • University of Lausanne Hospitals

    collaborator OTHER

  • Kantonsspital Liestal

    collaborator OTHER

  • Schulthess Klinik

    collaborator OTHER

  • Andrej Trampuz

    lead OTHER

Principal Investigators

  • Andrej Trampuz · Centre hospitaliere universitaire vaudvoise (CHUV) University Hospital of Lausanne

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2014-06-30
Completion
2016-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01144000 on ClinicalTrials.gov